comparemela.com

Latest Breaking News On - Focal segmental glomerulosclerosis - Page 8 : comparemela.com

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNivi nehraJula inrigNaomi eichenbaumExchange commissionCorporate communicationsUniversity of leicester studyAmerican society of nephrologyTravere therapeutics incPresent abstractsAmerican societyKidney weekFocal segmental glomerulosclerosisAbstract sessionHigh impact clinical

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNaomi eichenbaumJula inrigNivi nehraCorporate communicationsExchange commissionTravere therapeutics incUniversity of leicester studyAmerican society of nephrologyAmerican societyKidney weekFocal segmental glomerulosclerosisAbstract sessionHigh impact clinicalPediatric patients

18 Share Tips | 26th June 2023

Take a look at the buy, hold and sell recommendations for the week of 26th June 2023 from 3 top experts.

United kingdomGolden groveSouth australiaMount dimerWestern australiaJohnson rangeNew zealandNew south walesCliff headAngus geddesTony locantroChristopher wattDiagnosticum laboratory groupTransurban groupHarvey norman holdingsAustralian prudential regulation authority

Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform

/PRNewswire/ Delta4, a pioneering digital drug discovery company specializing in identifying new therapeutic indications for drugs with established safety.

Paul percoKurt herpelPrnewswire deltaTranslational researchFocal segmental glomerulosclerosisBiology lead

Inaxaplin reduces proteinuria in focal segmental glomerulosclerosis with two APOL1 variants

1. In preclinical studies, inaxaplin selectively inhibited apolipoprotein L1 (APOL1) in vitro and reduced proteinuria in a APOL1 G2-homologous transgenic mouse model of proteinuric kidney disease. 2. In a following phase 2a clinical study, 13 participants treated with inaxaplin had a significant reduction in urinary protein-to-creatinine ratio at week 13. Evidence Rating Level: 3 (Average)

Minute medicine incRating levelConfidence intervalApol1 variantsChronic diseaseFocal segmental glomerulosclerosisProteinuric kidney disease

vimarsana © 2020. All Rights Reserved.